Safety and immunogenicity of influenza whole inactivated virus vaccines: A phase i randomized clinical trial

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 4, 2015, Pages 983-990

  Van Boxtel, Renée A J ^a   Verdijk, Pauline ^b   de Boer, Otto J ^b   van Riet, Elly ^b   Mensinga, Tjeert T ^c   Luytjes, Willem ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b Institute for Translational Vaccinology (Intravacc)   (Netherlands)

^c QPS   (Netherlands)

Author keywords

Immunogenicity; Influenza; Pandemic; Phase I trial; Safety; Seasonal; Whole inactivated virus vaccine

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INACTIVATED VIRUS VACCINE; PANDEMIC WHOLE INACTIVATED VIRUS VACCINE; PLACEBO; SEASONAL WHOLE INACTIVATED VIRUS VACCINE; UNCLASSIFIED DRUG; INACTIVATED VACCINE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DIZZINESS; DRUG SAFETY; ECCHYMOSIS; ERYTHEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; LOCAL SKIN REACTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA; OROPHARYNX PAIN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RHINORRHEA; SEROCONVERSION; SHIVERING; SKIN INDURATION; SWELLING; VACCINE PRODUCTION; VOMITING; CLINICAL TRIAL; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN;

HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; VACCINES, INACTIVATED;

EID: 84930939461     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1012004     Document Type: Article

References (38)

1. Monto AS. Influenza: quantifying morbidity and mortality. Am J Med 1987; 82:20-5; PMID:3591814; http://dx. doi. org/10. 1016/0002-9343(87)90556-0
2. Palese P, Garcia-Sastre A. Influenza vaccines: present and future. J Clin Invest 2002; 110:9-13; PMID:12093881; http://dx. doi. org/10. 1172/ JCI0215999
3. Poland GA, Ovsyannikova IG, Jacobson RM. Immunogenetics of seasonal influenza vaccine response. Vaccine 2008; 26:D35-40; PMID:19230157; http://dx. doi. org/10. 1016/j. vaccine. 2008. 07. 065
4. Nichol KL. Efficacy and effectiveness of influenza vaccination. Vaccine 2008; 26:D17-22; PMID:19230153; http://dx. doi. org/10. 1016/j. vaccine. 2008. 07. 048
5. Oshitani H, Kamigaki T, Suzuki A. Major issues and challenges of influenza pandemic preparedness in developing countries. Emerg Infect Dis 2008; 14:875-80; PMID:18507896; http://dx. doi. org/ 10. 3201/eid1406. 070839
6. World Health Organization. Pandemic preparedness and response. WHO Guidance document 2009. [Last viewed on March 10, 2015] Available at http://www. who. int/influenza/resources/documents/pandemic_ guidance_04_2009/en/
7. Kieny MP, Costa A, Hombach J, Carrasco P, Pervikov Y, Salisbury D, Greco M, Gust I, LaForce M, Franco-Paredes C, et al. A global pandemic influenza vaccine action plan. Vaccine 2006; 24:6367- 70; PMID:17240560; http://dx. doi. org/10. 1016/j. vaccine. 2006. 07. 021
8. World Health Organization. Global pandemic influenza action plan to increase vaccine supply. 2006. [Last viewed on march 10, 2015] Available at http://www. who. int/csr/resources/publications/influenza/ WHO_CDS_EPR_GIP_2006_1/en/
9. World Health Organization. Pandemic influenza vaccines: current status. Pandemic (H1N1) 2009 11. 2009
10. Jadhav S, Datla M, Kreeftenberg H, Hendriks J. The developing countries vaccine manufacturers' network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Vaccine 2008; 26:1611-5; PMID:18294742; http://dx. doi. org/ 10. 1016/j. vaccine. 2008. 01. 034
11. Hendriks J, Holleman M, de Boer O, de Jong P, Luytjes W. An international technology platform for influenza vaccines. Vaccine 2011; 29 1:A8-11; PMID:21684431; http://dx. doi. org/10. 1016/j. vaccine. 2011. 04. 124
12. World Health Organization. Recommendations for the production and control of influenza vaccine (inactivated). WHO Tech Rep Series, No. 927, 2005, 3. 2005
13. Stephenson I, Nicholson KG, Gluck R, Mischler R, Newman RW, Palache AM, Verlander NQ, Warburton F, Wood JM, Zambon MC. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/ 1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003; 362:1959-66; PMID:14683655; http://dx. doi. org/10. 1016/S0140- 6736(03)15014-3
14. Parkman PD, Hopps HE, Rastogi SC, Meyer HM, Jr. Summary of clinical trials of influenza virus vaccines in adults. J Infect Dis 1977; 136 S722-30; PMID:606797; http://dx. doi. org/10. 1093/infdis/136. Supplement_3. S722
15. Beyer WE, Palache AM, Osterhaus AD. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature. Clin Drug Invest 1998; 15:1-12; PMID:18370460; http://dx. doi. org/10. 2165/ 00044011-199815010-00001
16. Zabel F, Kundig TM, Bachmann MF. Virusinduced humoral immunity: on how B cell responses are initiated. Curr Opin Virol 2013; 3:357-62; PMID:23731601; http://dx. doi. org/ 10. 1016/j. coviro. 2013. 05. 004
17. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010; 10:787-96; PMID:20948547; http://dx. doi. org/10. 1038/nri2868
18. Geeraedts F, Bungener L, Pool J, ter Veer W, Wilschut J, Huckriede A. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenz Other Res Virus 2008; 2:41-51; PMID:19453471; http://dx. doi. org/10. 1111/j. 1750- 2659. 2008. 00038. x
19. Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, Pool J, Wilschut J, Fitzgerald KA, Huckriede A. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog 2008; 4: e1000138; PMID:18769719; http://dx. doi. org/ 10. 1371/journal. ppat. 1000138
20. Hovden AO, Cox RJ, Haaheim LR. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scandinavian j Immunol 2005; 62:36-44; PMID:16092921; http://dx. doi. org/ 10. 1111/j. 1365-3083. 2005. 01633. x
21. Budimir N, Huckriede A, Meijerhof T, Boon L, Gostick E, Price DA, Wilschut J, de Haan A. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity. PLoS One 2012; 7:e30898; PMID:22303469; http://dx. doi. org/10. 1371/journal. pone. 0030898
22. Beigel JH, Voell J, Huang CY, Burbelo PD, Lane HC. Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine. J Infect Dis 2009; 200:501-9; PMID:19569973; http:// dx. doi. org/10. 1086/599992
23. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424-35; PMID:19745215; http://dx. doi. org/10. 1056/NEJMoa0907650
24. Nolan T, McVernon J, Skeljo M, Richmond P, Wadia U, Lambert S, Nissen M, Marshall H, Booy R, Heron L, et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010; 303:37- 46; PMID:20026597; http://dx. doi. org/10. 1001/ jama. 2009. 1911
25. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010; 375:41-8; PMID:20018365; http://dx. doi. org/10. 1016/S0140-6736(09)62026-2
26. Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, Graham IL, Noah DL, He F, Hill H. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008; 197:667-75; PMID:18260764; http://dx. doi. org/10. 1086/527489
27. Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, Hons E, Devaster JM, Leroux- Roels G. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-9; PMID:17707753; http://dx. doi. org/ 10. 1016/S0140-6736(07)61297-5
28. Soema PC, Rosendahl Huber SK, Willems GJ, Jiskoot W, Kersten GF, Amorij JP. Influenza T-cell Epitope- Loaded Virosomes Adjuvanted with CpG as a potential Influenza vaccine. Pharm Res 2014; PMID:25344321 Open Acess. Available at http://link. springer. com/article/ 10. 1007/s11095-014-1556-3/fulltext. html
29. Sansyzbay AR, Erofeeva MK, Khairullin BM, Sandybayev NT, Kydyrbayev ZK, Mamadaliyev SM, Kassenov MM, Sergeeva MV, Romanova JR, Krivitskaya VZ, et al. An inactivated, adjuvanted whole virion clade 2. 2 H5N1 (A/chicken/astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans. Clin Vaccine Immunol 2013; 20:1314-9; PMID:23803900; http://dx. doi. org/10. 1128/ CVI. 00096-13
30. Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, et al. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clin Infect Dis 2009; 48:1087-95; PMID:19281330; http://dx. doi. org/10. 1086/597401
31. Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006; 368:991-7; PMID:16980114; http://dx. doi. org/10. 1016/S0140- 6736(06)69294-5
32. Ikeno D, Kimachi K, Kino Y, Harada S, Yoshida K, Tochihara S, Itamura S, Odagiri T, Tashiro M, Okada K, et al. Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection. Microbiol Immunol 2010; 54:81-8; PMID:20377741; http://dx. doi. org/10. 1111/j. 1348- 0421. 2009. 00191. x
33. Beran J, Abdel-Messih IA, Raupachova J, Hobzova L, Fragapane E. A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. Clin Ther 2010; 32:2186-97; PMID:21316535; http://dx. doi. org/10. 1016/S0149- 2918(11)00024-5
34. Vesikari T, Forsten A, Herbinger KH, Cioppa GD, Beygo J, Borkowski A, Groth N, Bennati M, von Sonnenburg F. Safety and immunogenicity of an MF59 ((R))-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine 2012; 30:1388- 96; PMID:22192847; http://dx. doi. org/10. 1016/j. vaccine. 2011. 12. 009
35. van Els C, Mjaaland S, Naess L, Sarkadi J, Gonczol E, Smith Korsholm K, Hansen J, de Jonge J, Kersten G, Warner J, et al. Fast vaccine design and development based on correlates of protection (COPs): Influenza as a trendsetter. Hum Vaccin Immunother 2014; 10:1935-48; PMID:25424803; http://dx. doi. org/ 10. 4161/hv. 28639
36. Reber A, Katz J. Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines 2013; 12:519-36; PMID:23659300; http://dx. doi. org/10. 1586/erv. 13. 35
37. World Health Organization. Guidelines on clinical evaluation of vaccines: regulatory expectations. WHO Tech Rep Ser No. 924, 2004, 1. 2004.
38. Palmer D, Dowle, W., Coleman, M., and Schild, G. Haemagglutination inhibition test. Advanced laboratory techniques for influenza diagnosis: procedural guide. Atlanta, GA: US. Dep Health Edu Welfare 1975:25-62.